ArticleBreast cancer (Tokyo, Japan)2026
Efficacy of xeno-free induced mesenchymal stem/stromal cells in enhancing autologous fat graft survival.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundBreast reconstruction using autologous fat grafting offers a less invasive alternative with shorter surgical times compared to traditional flap procedures. Although adipose-derived stem cells (ASCs) have improved fat graft survival rates, the variability in mesenchymal stem cells (MSCs) quality due to donor health and medication intake poses challenges. MSCs derived from induced pluripotent stem cells (iPSC-MSCs) demonstrate enhanced proliferative and immunomodulatory properties that may further enhance outcomes.
methodsWe harvested human adipose tissue from surgical specimens and isolated ASCs. We used human iPSC-MSCs generated through a neural crest cell lineage under xeno-free conditions (iMSCs), to assess the improvement in survival and integration of autologous human adipose tissue grafts in BALB/c-nu/ + mice. We compared outcomes in groups treated with phosphate-buffered saline (PBS), ASCs, and iMSCs over 28 days, focusing on fat graft retention, fibrosis, and neovascularization, and adipogenic differentiation using vimentin/perilipin immunofluorescence staining.
resultsiMSC treatment significantly preserved graft area (82.3 ± 20.5%) compared to PBS controls (50.6 ± 28.7%) and ASC treatments (65.3 ± 24.7%). It also resulted in the lowest fibrosis (7,748.7 ± 6,018.6 µm2) and highest neovascularization (68,681.5 ± 21,363.4 µm2), indicating improved tissue integration and vascularization. The proportion of vimentin-positive/perilipin-positive cells—indicative of adipogenic differentiation—was significantly higher in the iMSC group (7.46%) compared to PBS (4.51%, p = 0.025).
conclusioniMSCs may enhance fat graft survival through both paracrine signaling and adipogenic differentiation, supporting a dual mechanism of action. These findings highlight their potential as a standardized, high-performance cellular adjunct for improving surgical outcomes in breast reconstruction and potentially other regenerative medicine applications. Further studies incorporating cell tracking techniques are warranted to confirm the direct differentiation potential of iMSCs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.